Molecular Genetics and Metabolism
-
Publication Venue For
-
Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy..
133:261-268.
2021
-
New insights into GI manifestations in late-onset Pompe disease: Lessons from the bench and bedside.
132:S58-S59.
2021
-
Characterization of dermatan sulfate and chondroitin sulfate in tissues from a mouse model of mucopolysaccharidosis type VI using UPLC-MS/MS.
129:S165-S165.
2020
-
The emerging phenotype of late-onset Pompe disease: A systematic literature review..
120:163-172.
2017
-
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation..
120:96-100.
2017
-
Living related versus deceased donor liver transplantation for maple syrup urine disease..
117:336-343.
2016
-
Mouse model of glycogen storage disease type III
2014
-
To the Editor.
107:244.
2012
-
Erratum to "Pompe disease: Design, methodology, and early findings from the Pompe Registry" [Mol. Genet. Metabol. 103 (2011) 1-11].
104:424.
2011
-
INFLUENCE OF CROSS-REACTING IMMUNOLOGIC MATERIAL STATUS ON TREATMENT OUTCOMES IN INFANTILE POMPE PATIENTS TREATED WITH RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE.
98:59-59.
2009
-
LIFE EXPECTANCY AND CAUSE OF DEATH IN MALES AND FEMALES WITH FABRY DISEASE: FINDINGS FROM THE FABRY REGISTRY.
98:59-59.
2009
-
LONG-TERM SURVIVAL AND CORRECTION OF BIOCHEMICAL ABNORMALITIES FOLLOWING GENE THERAPY IN DOGS WITH GLYCOGEN STORAGE DISEASE TYPE 1A.
98:45-45.
2009
-
PROGRESS IN THE DEVELOPMENT OF RAAV2/8 VECTOR-MEDIATED, LIVER-DIRECTED GENE THERAPY FOR PHENYLKETONURIA (PKU).
98:37-37.
2009
-
SULFITE OXIDASE AND MOLYBDENUM COFACTOR DEFICIENCIES: CLINICAL EXPERIENCE OF A DIAGNOSTIC LABORATORY AND LITERATURE REVIEW.
98:139-139.
2009
-
115. Immune-modulation therapy in a CRIM negative Pompe disease patient blocks antibody formation towards Myozyme, reverses cardiomyopathy, and prolongs survival.
96:S37-S37.
2009
-
53. DTI with quantitative tractography as a marker of disease progression in newborns with Krabbe disease.
96:S23-S24.
2009
-
7. An efficient high-risk screening protocol for Fabry disease.
96:S13-S13.
2009
-
77. Cross-reacting immunologic material status affects outcomes in infants with Pompe disease treated with alglucosidase alfa.
96:S28-S29.
2009
-
Erratum to "Rapid diagnosis of late-onset Pompe disease by fluorometric assay of α-glucosidase activities in dried blood spots" [Mol. Genet. Metab. 90 (2007) 449-452] (DOI:10.1016/j.ymgme.2006.12.006).
92:285.
2007
-
Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots..
90:449-452.
2007
-
Glutaric acidemia type 1 in patients of Lumbee heritage from North Carolina..
88:90-92.
2006
-
Biochemical properties of recombinant human and mouse N-acetylglutamate synthase..
87:226-232.
2006
-
Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease..
85:247-254.
2005
-
Hyperinsulinism/Hyperammonemia Syndrome: a synopsis..
84:101-103.
2005
-
Decreased expression of lysyl hydroxylase 2 (LH2) in skin fibroblasts from three Ehlers-Danlos patients does not result from mutations in either the coding or proximal promoter region of the LH2 gene..
83:312-321.
2004
-
Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria..
78:291-294.
2003
-
Methylation of the FSHD syndrome-linked subtelomeric repeat in normal and FSHD cell cultures and tissues..
74:322-331.
2001
-
Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of Ehlers-Danlos syndrome type VI..
71:212-224.
2000
-
Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease..
69:16-23.
2000
-
A patient with Ehlers-Danlos syndrome type VI is homozygous for a premature termination codon in exon 14 of the lysyl hydroxylase 1 gene..
67:74-82.
1999
-
Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/-
mouse model.
2021
-
Comparison of psychosine analysis in dried blood spots and red blood cells in Krabbe disease
2021
-
Improved sample collection method for nicotinamide adenine dinucleotide measurement from whole blood
2021
-
Mini-COMET: effects of avalglucosidase alfa on ptosis in participants with infantile-onset Pompe disease previously treated with alglucosidase alfa
2021
-
Urinary glucose tetrasaccharide correlates with phenotype in Pompe disease in the newborn period
2021
-
Utilization of in-patient genetic testing services at Duke University Health System
2021
-
Functional analysis and clinical curation of human acid alpha glucosidase (GAA) variants of unknown significance (VUS) screened from infants diagnosed with Pompe disease via newborn screening (NBS)
2021
-
Glycogen accumulation in smooth muscle in the Pompe disease mouse
2021
-
Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice
2021
-
Mini-COMET study: Effects of repeat avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa
2021
-
Phenotypic target organ and biomarker variation within a family with late onset Fabry disease
2021
-
A new look at an old disease: Is Pompe disease a neuromuscular disorder with CNS involvement?
2020
-
A phase 1 study of gene therapy with ACTUS-101 in late-onset Pompe disease
2020
-
Comparisons of infant and adult mice reveal age effects for liver depot gene therapy in Pompe disease
2020
-
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease
2020
-
Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3
2020
-
COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA
2019
-
EVALUATION OF PLASMA GLUCOSYLSPHINGOSINE AND GALACTOSYLSPHINGOSINE IN PATIENTS WITH GAUCHER DISEASE
2019
-
QUANTITATIVE EVALUATION OF WHITE MATTER HYPERINTENSITIES IN THE CENTRAL NERVOUS SYSTEM IN INFANTILE POMPE DISEASE
2019
-
SUMMARY OF SCREENING DATA FROM 19 PATIENTS WITH LATE-ONSET POMPE DISEASE FOR A PHASE I CLINICAL TRIAL OF AAV VECTOR-MEDIATED GENE THERAPY
2019
-
COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA
2019
-
EVALUATION OF PLASMA GLUCOSYLSPHINGOSINE AND GALACTOSYLSPHINGOSINE IN PATIENTS WITH GAUCHER DISEASE
2019
-
QUANTITATIVE EVALUATION OF WHITE MATTER HYPERINTENSITIES IN THE CENTRAL NERVOUS SYSTEM IN INFANTILE POMPE DISEASE
2019
-
SUMMARY OF SCREENING DATA FROM 19 PATIENTS WITH LATE-ONSET POMPE DISEASE FOR A PHASE I CLINICAL TRIAL OF AAV VECTOR-MEDIATED GENE THERAPY
2019
-
Changing the clinical course of infantile Pompe disease with immune modulation strategies: 12 years of experience
2019
-
Parent report of school functioning and behavior in children with Pompe disease
2019
-
Quantification of glucosylsphingosine in plasma/serum by UPLC-MS/MS
2019
-
Quantitative evaluation of white matter hyperintensities in the central nervous system in infantile Pompe disease
2019
-
Salmeterol with liver depot gene enhances the skeletal muscle response in murine Pompe disease
2019
-
A FIRST REPORT OF CHOLANGIOCARCINOMA IN GSD I
2018
-
BEZAFIBRATE TREATMENT ENHANCES EFFICIENCY OF AAV GENE THERAPY ON GLYCOGEN STORAGE DISEASE TYPE IA
2018
-
CLINICAL COURSE AND OUTCOME IN ADULTS WITH PROPIONIC ACIDEMIA: CASE SERIES
2018
-
OVERVIEW OF NUCLEIC ACID THERAPIES
2018
-
A prediction model to identify infantile Pompe disease (IPD) patients at high-risk of developing significant anti-drug antibodies (ADA) utilizing acid α-glucosidase (GAA ) variants and HLA-type
2018
-
An immune tolerance approach using methotrexate in the naïve setting of patients treated with a therapeutic protein: Experience in infantile Pompe disease
2018
-
Cognition and brain involvement in infantile Pompe disease
2018
-
Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT
2018
-
Efficient and effective newborn screening (NBS) for early infantile Krabbe diseases (KD)
2018
-
First-in-human preliminary pharmacokinetic data on a novel recombinant acid α-glucosidase, ATB200, co-administered with the pharmacological chaperone, AT2221, in patients with late-onset Pompe disease
2018
-
Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T > G “late-onset” GAA variant
2018
-
Lingual pathophysiology in late-onset Pompe disease
2018
-
Plasma lyso-Gb3 as a diagnostic marker for Fabry disease
2018
-
Psychosine: A useful biomarker for newborn screening, follow up and monitoring of Krabbe disease
2018
-
Respiratory muscle training in Pompe disease
2018
-
Survey of quality of life, phenotypic expression and response to treatment in patients with Krabbe leukodystrophy
2018
-
The patient and clinician point of view: living with late-onset Pompe disease
2018
-
A newborn screening dilemma: when to treat Pompe disease with c.-32-13T>/;G IVS splice site mutation
2017
-
Beneficial effects of carvedilol with enzyme replacement therapy in Pompe disease
2017
-
Characteristics of 27 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher Outcome Survey
2017
-
Early initiation of prophylactic immune tolerance induction and enzyme replacement therapy in prenatally diagnosed infantile onset Pompe disease with a CRIM-negative mutation
2017
-
Immunomodulation to enzyme replacement therapy with tolerogenic nanoparticles containing rapamycin in a murine model of Pompe disease
2017
-
Impact of earlier treatment on respiratory function in patients with late-onset Pompe disease: data from the Pompe Registry
2017
-
Late-onset Pompe disease with atypical presentation: What else is going on?
2017
-
Outside the fiber: interstitial pathology of skeletal muscle in infantile Pompe disease
2017
-
PRKAG2 as a mimicker of Pompe disease
2017
-
Respiratory muscle training in late-onset Pompe disease
2017
-
Sequence variants and genotypes among 898 patients with Pompe disease: data from the Pompe Registry
2017
-
Transformation in pre-treatment presentations of Gaucher disease during the first two decades of imiglucerase enzyme replacement therapy: a report from the International Collaborative Gaucher Group Gaucher Registry
2017
-
DIABETES MELLITUS AND GLYCOGEN STORAGE DISEASE TYPE 1A IN AN ADULT FEMALE: A CASE STUDY
2016
-
IDENTIFICATION OF MODIFIER GENES OF POMPE DISEASE PHENOTYPE BY VARIANT ANALYSIS OF WHOLE EXOME SEQUENCING DATA
2016
-
INFUSION-ASSOCIATED REACTIONS AND IMMUNOGENICITY IN THE ADVANCE STUDY OF ALGLUCOSIDASE ALFA PRODUCED AT 4000 L SCALE IN PATIENTS WITH POMPE DISEASE
2016
-
SMALL FIBER NEUROPATHY IN A COHORT OF PATIENTS WITH GLYCOGEN STORAGE DISEASE TYPE III
2016
-
52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study
2016
-
Clinical characteristics and genotypes in the ADVANCE baseline dataset, a comprehensive cohort of us children and youth with Pompe disease
2016
-
Cross-reactive immunologic material positive infantile Ρompe disease: Characterization of immune responses in patient treated with enzyme replacement therapy
2016
-
Differentially expressed proteins in infantile Pompe disease: prediction of patients likely to mount an immune response to enzyme replacement therapy
2016
-
Electrocardiograph findings when screening for initiation of oral substrate reduction therapy with eliglustat for treatment of Gaucher disease
2016
-
Enzyme replacement therapy rate escalation in infantile onset Pompe disease
2016
-
Identification of modifier genes of Pompe disease phenotype by variant analysis of whole exome sequencing data
2016
-
Late onset Pompe disease case review: Severe isolated hypertrophic cardiomyopathy
2016
-
Long-term immune tolerance of infantile Pompe disease with entrenched immune responses to ERT using a bortezomib-based regimen
2016
-
Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy
2016
-
New perspectives for ERT in Pompe disease: Extending the action of the enzyme to cytosolic targets
2016
-
Platelet response to enzyme replacement therapy and oral substrate reduction therapy in an adult with Gaucher disease
2016
-
Prophylactic immune modulation in infantile Ρompe disease using low-dose methotrexate induction: A safe, inexpensive, widely accessible, and efficacious strategy
2016
-
Quantification of dermatan sulfate and heparan sulfate in cerebrospinal fluid using liquid chromatography-tandem mass spectrometry for therapeutic monitoring of patients with mucopolysaccharidoses
2016
-
Three cases of familial pseudodominance in Pompe disease: Are current practices missing diagnostic and treatment opportunities?
2016
-
A family with X-linked creatine transporter deficiency diagnosed by whole exome sequencing
2015
-
A hypophosphatasia case series: Odontohypophosphatasia or childhood/adult form?
2015
-
BIOENGINEERED HUMAN MUSCLE FOR PHYSIOLOGICAL STUDIES AND DISEASE MODELING
2015
-
Urinary glucose tetrasaccharide concentrations in patients with infantile and late-onset Pompe disease identified by newborn screening
2015
-
Zinc finger nuclease-induced targeted integration of a glucose-6-phosphatase gene promotes survival in mice with glycogen storage disease type-IA
2015
-
Avascular necrosis in neuronopathic Gaucher despite high-dose enzyme replacement therapy
2015
-
Characterization of gait in late onset Pompe disease
2015
-
Consideration of increased dosing of alglucosidase alfa to achieve improved clinical outcomes in infantile Pompe disease
2015
-
Dietary intake of individuals with late onset Pompe disease: A review and comparison to current diet recommendations
2015
-
Discordant clinical responses in CRIM-positive IPD siblings demonstrate need for prophylactic ITI in the naive setting
2015
-
Further expanding the phenotype of treated infantile onset Pompe disease
2015
-
Prophylactic immume modulation in infantile Pompe disease: Collective experience treating CRIM-positive and negative patients in the naive setting
2015
-
Proteomics to identify signature proteins in patients likely to mount an immune response to enzyme replacement therapy in infantile Pompe disease
2015
-
Risk factors for severe clinical events and the incidence of these events in male and female patients with Fabry disease treated with agalsidase beta
2015
-
The Pompe Registry: 10years of data
2015
-
DRIED BLOOD SPOT ENZYMATIC ASSAYS FOR MPS TYPE IVA (MORQUIO) AND TYPE VI (MAROTEAUX-LAMY) SYNDROMES
2014
-
OPTIMIZING METABOLIC CONTROL OF GLYCOGEN STORAGE DISEASE TYPE 3 (GSD3): POTENTIAL ROLE FOR MEDIUM CHAIN TRIGLYCERIDES (MCT)
2014
-
Attention and corpus callosum volumes in individuals with Hurler and Hurler-Scheie syndromes and controls
2014
-
Expanding our understanding of incontinence and lower urinary tract symptoms in adults with Pompe disease
2014
-
Outcome of pregnancy in Pompe disease with and without enzyme replacement therapy
2014
-
Pilot study of adjunctive albuterol in late-onset Pompe disease reveals safety and efficacy from upregulated Mannose-6-phosphate receptor expression
2014
-
Quantitative whole-body muscle MRI, clinical muscle group weakness, and muscle-map correlation in adult patients with Pompe disease
2014
-
Small fiber neuropathy in late-onset Pompe disease: a case report and prospective screening
2014
-
Survival and developmental milestones among Pompe registry patients with classic infantile-onset Pompe disease with different timing of initiation of treatment with enzyme replacement therapy (ERT)
2014
-
The development and validation of dried blood spot enzymatic assays for MPS type IV A (Morquio) and type VI (Maroteaux-Lamy) syndromes
2014
-
The emerging natural history of cross-reactive immunologic material (CRIM)-negative infantile Pompe disease patients treated with recombinant human GAA
2014
-
A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease
2013
-
Characterization of differential tissue GAA content and CI-M6PR/IGF2R expression using autopsy material obtained from 2 patients with CRIM-negative infantile Pompe disease treated with ERT
2013
-
The importance of targeting the central nervous system for treatment of respiratory insufficiency in Pompe disease
2013
-
A canine model of glycogen storage disease type III
2012
-
Assessment of urinary globotriaosylsphingosine (lyso-Gb(3)), globotriaosylceramide (gb(3)) by LC-MS/MS in patients with fabry disease
2012
-
Clinical challenges diagnosing an infant with hypertrophic cardiomyopathy
2012
-
Hypophosphatasia: Enzyme replacement therapy (ENB-0040) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults
2012
-
Long term treatment of glycogen storage disease type IA: Clinical summary of a canine model
2012
-
Outcomes of isolated liver and simultaneous liver-kidney transplantation in two patients with glycogen storage disease type lb
2012
-
Quantification of glycosaminoglycans in human urine and mouse tissue by UPLC-MS/MS
2012
-
Rapamycin is a potential therapy for glycogen storage disease type III
2012
-
Beta2 Agonists Enhance Efficacy of Enzyme Replacement Therapy in Murine Pompe Disease
2012
-
Characteristics Associated with Delays in Diagnosis of Pompe Disease Among Patients Enrolled in the Pompe Registry
2012
-
Evaluation of Globotriaosylceramide (GL-3) Accumulation in 18 Patients with Fabry Disease Nephropathy. Podocytes are More Severely Affected than Peritubular Capillaries
2012
-
Immunological Challenges in Late-Onset Pompe Disease Treated with Enzyme Replacement Therapy
2012
-
Long Term Outcome and Clinical Experience on Immune Tolerance Induction Therapies in Infantile Pompe Disease
2012
-
Predicting Cross Reactive Immunological Material (CRIM) Status in Pompe Disease Using GAA Mutations: Lessons Learned from 10 Years of Clinical Laboratory Testing Experience
2012
-
Presenting Signs and Symptoms Among Patients with Pompe Disease Enrolled in the Pompe Registry
2012
-
Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension
2012
-
Elevation of guanidinoacetate in the newborn blood spot of a patient with guanidinoacetate methyltransferase deficiency
2011
-
Metabolic predictors of coagulation abnormalities in glycogen storage disease type 1
2011
-
Monitoring urinary glucose tetrasaccharide biomarker in patients with infantile and late-onset Pompe disease identified through newborn screening
2011
-
Novel application of bortezomib in abrogating antibodies against ERT in Pompe disease: A strategy for broad clinical application in diseases treated with therapeutic proteins
2011
-
The emerging phenotype of long-term infantile Pompe survivors on enzyme replacement therapy
2011
-
Why 5-methyltetrahydrofolate may be preferred to folinic acid in severe MTHFR deficiency complicated by cerebral folate deficiency. Results of an "n-1-clinical trial"
2011
-
Bortezomib: A solution to the challenge of antibodies in diseases treated with therapeutic proteins?
2011
-
Efficient urine filter paper mass spectrometry methodology for glycosaminoglycan quantification
2011
-
MPS I: Age at transplant is associated with better long-term developmental outcomes
2011
-
MPS II: developmental outcomes after hematopoietic stem cell transplantation
2011
-
Mannose-6-Phosphate receptor expression modulates efficacy from enzyme replacement therapy in Pompe disease
2011
-
Novel quantitative method to evaluate GL-3 inclusions in renal peritubular capillaries (PTCs) in patients with Fabry disease (FD) by virtual microscopy (VM)
2011
-
The clinical phenotype of Long-term infantile Pompe disease survivors
2011
-
The effect of exercise on improving strength and function in a Pompe mouse model treated with AAV vector mediated gene therapy
2011
-
The heterogeneity of pompe disease: Early data on genotype from the Pompe registry
2011
-
The pompe registry: Baseline data from the first five years
2011
-
BJORNSTAD SYNDROME IN A BOY WITH SENSORINEURAL HEARING LOSS, PILI TORTI, MENTAL RETARDATION, SEIZURES AND COMPLEX III DEFICIENCY
2010
-
HIGHLY EFFICACIOUS GENE THERAPY IN THE CANINE MODEL FOR GLYCOGEN STORAGE DISEASE TYPE IA
2010
-
SEVERE NEONATAL LACTIC ACIDOSIS IN A MALE INFANT WITH A PDH E1 ALPHA FRAME SHIFT MUTATION IN THE C-TERMINAL REGION: COULD WE PREDICT THE OUTCOME?
2010
-
THE ROLE OF ANTI-rhGAA ANTIBODY TITERS AND CLINICAL OUTCOMES IN INFANTILE POMPE DISEASE PATIENTS
2010
-
7. A urinary glycosaminoglycan analysis by tandem mass spectrometry
2010
-
74. Immunological aspects of treatment of Pompe disease
2010
-
8. How useful is urinary lyso-Gb3 as a biomarker for Fabry disease?
2010
-
BIOMARKER ANALYSIS FOR PYRIDOXINE DEPENDENT SEIZURES AND FOLINIC ACID RESPONSIVE SEIZURES
2009
-
UTILITY OF A URINARY TETRASACCHARIDE AS A BIOMARKER FOR GLYCOGEN STORAGE DISEASE TYPE III
2009
-
75. Clinical signs and symptoms of Pompe disease in 120 infantile-onset and 373 late-onset patients: A report from the Pompe Registry
2009
-
76. CRIM responses in Pompe disease
2009
-
Long-term monitoring of patients with infantile-onset pompe disease using a urinary tetrasaccharide biomarker.
2008
-
Quantification of 2,3-dinor-F-2-isoprostanes as a biornarker of oxidative stress in urine by UPLC-LC-ESI-MSIMS: A convenient method for highthroughput analysis.
2008
-
30. Long-term developmental follow-up of babies treated for infantile Krabbe disease with unrelated cord blood transplantation
2008
-
52. Effect of dose of enzyme replacement therapy with imiglucerase on bone crises in adolescents with Gaucher disease
2008
-
53. The Pompe Registry: Centralized data collection to track the natural course of Pompe disease
2008
-
66. Development of a disease severity scoring system for patients with Pompe disease
2008
-
Muscle-targeted gene therapy in glycogen storage disease type II with adeno-associated virus serotypes 7, 8, and 9
2008
-
68 Diagnosing and treating Pompe disease, long term outcome and risk factors
2007
-
70 Enhanced response to enzyme replacement therapy in Pompe disease following the induction of immune tolerance
2007
-
Dried blood spot assay for Pompe disease: diagnostic experience of the duke biochemical genetics laboratory.
2007
-
Highly efficacious gene therapy in glycogen storage disease type Ia (GSD-Ia) with a double-stranded AAV vector.
2007
-
Diagnostic value of urinary and plasma glucose tetrasaccharides in infantile and late onset glycogen storage disease type II.
2005
-
Efficacy of an adeno-associated virus (AAV) vector administered to glycogen storage disease type Ia (GSD-Ia) mice at mid-infancy.
2005
-
A comparison of mass spectrometry methods for the measurement of creatine and guanidinoacetate in plasma.
2004
-
Elevated chitotriosidase activity in CSF in patients with GM1 and GM2 gangliosidosis: a surrogate marker of disease progression?
2004
-
Elevated chitotriosidase activity in CSF in patients with tay-Sachs disease: a surrogate marker of disease progression?
2004